Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 5/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.41 |
| ▸ | IL2 | P60568 | 1/20 | 0.40 |
| ▸ | MPL | P40238 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30326145 | 1.00 | PDE2A (0.46) | PDE2ATRPV1IDO1HSD11B1ALDH1A1 | |
| SCHEMBL16971901 | 0.82 | RAPGEF4 (0.37) | PDE2ATRPV1HSD11B1ALDH1A1TSHR | |
| SCHEMBL30271700 | 0.82 | RAPGEF4 (0.37) | PDE2ATRPV1HSD11B1ALDH1A1TSHR | |
| SCHEMBL29827335 | 0.81 | PDE2A (0.50) | PDE2ATRPV1IDO1HSD11B1ALDH1A1 | |
| SCHEMBL230800 | 0.81 | PDE2A (0.50) | PDE2ATRPV1IDO1HSD11B1ALDH1A1 | |
| SCHEMBL8110620 | 0.80 | PDE2A (0.45) | PDE2ATRPV1IDO1HSD11B1TSHR | |
| SCHEMBL29402881 | 0.80 | TSHR (0.61) | PDE2AALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL980201 | 0.80 | TSHR (0.61) | PDE2AALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL3951887 | 0.79 | ESR1 (0.40) | HSD11B1TSHRMEN1KMT2A | |
| SCHEMBL530212 | 0.79 | ALDH1A1 (0.41) | HSD11B1ALDH1A1TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0847977-B1 | 2,3-DIHALOGENO-6-TRIFLUOROMETHYLBENZENE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | NIPPON SODA CO (JP) | 2001-08-29 | — | — | EP | claimed |
| US-6054605-A | CHEMICAL INTERMEDIATE FOR DRUGS, PESTICIDES | NIPPON SODA CO., LTD. (JP) | 2000-04-25 | — | — | US | claimed |
| EP-0847977-A1 | 2,3-DIHALOGENO-6-TRIFLUOROMETHYLBENZENE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | NIPPON SODA CO., LTD. (JP) | 1998-06-17 | — | — | EP | claimed |
| JP-62036336-A | — | — | None | — | — | JP | disclosed |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12459927-B2 | Plasma kallikrein inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-116947903-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20230286958-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-09-14 | — | — | US | disclosed |
| EP-0159388-A2 | Preparation of nuclear chlorinated compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1985-10-30 | — | — | EP | disclosed |
| EP-0113625-B1 | PROCESS FOR THE PREPARATION OF TRIFLUOROMETHYLATED BENZENIC COMPOUNDS | RHONE-POULENC CHIMIE (FR) | 1985-07-10 | — | — | EP | disclosed |
| US-4470930-A | Preparation of nuclear chlorinated aromatic compounds | OCCIDENTAL CHEMICAL CORPORATION (US) | 1984-09-11 | — | — | US | disclosed |
| US-4469893-A | Method for the preparation of nitrodiphenyl ethers | OCCIDENTAL CHEMICAL CORPORATION (US) | 1984-09-04 | — | — | US | disclosed |
| US-4465508-A | Diphenyl ether herbicides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-08-14 | — | — | US | disclosed |
| EP-0113625-A1 | Process for the preparation of trifluoromethylated benzenic compounds | RHONE-POULENC CHIMIE (FR) | 1984-07-18 | — | — | EP | disclosed |
| EP-0023392-B1 | DIPHENYL ETHER COMPOUNDS, AND HERBICIDAL COMPOSITIONS AND PROCESSES UTILISING THEM | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-06-06 | — | — | EP | disclosed |
| US-4424396-A | ARYL HALIDE, A-AMINOACID | OCCIDENTAL CHEMICAL CORPORATION (US) | 1984-01-03 | — | — | US | disclosed |
| EP-0023392-A2 | Diphenyl ether compounds, and herbicidal compositions and processes utilising them | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1981-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | PDE2A 1600/4885TRPV1 3867/4885IDO1 1076/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | PDE2A 1600/4885TRPV1 3867/4885IDO1 1076/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | PDE2A 3080/4885TRPV1 4190/4885IDO1 1123/4885 |
| US-20230286958-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, KLK5 | PDE2A 1472/4885TRPV1 961/4885IDO1 1105/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | PDE2A 2194/4885TRPV1 4515/4885IDO1 1216/4885 |
| US-12459927-B2 | Plasma kallikrein inhibitors | KLKB1, SERPINE1, KLK5 | PDE2A 1472/4885TRPV1 961/4885IDO1 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.